CMS Opens Public Comment on Permanent Rules for Medicare Drug Price Negotiation: What It Means for Mental Health

On June 16, 2026, the Centers for Medicare and Medicaid Services (CMS) proposed a permanent rulebook for the Medicare Drug Price Negotiation Program. Most of it is technical. But a few pieces reach straight into how new mental health treatments get developed, funded, and delivered to the people who need them.

Medicare drug price negotiation raises real concerns for the research and innovation that patients depend on. But the policy is moving forward, so the practical questions matter now.

Here is the concern. The proposed rules shape which drugs get negotiated, how their prices are set, and what happens to companies working on the next generation of psychiatric medicines. Decisions like these are usually shaped by oncology and rare disease voices. Without input from the mental health community, the final rule almost certainly will be too.

Right now, there is an opportunity to for mental health advocates to weigh in on matters that could immeasurably impact mental health innovation. That is why this comment period matters, and why your voice belongs in it.

Comments are due August 17, 2026.

*Submit online through Regulations.gov. The STARR comment is available below to help guide your own comment.

What Is CMS Proposing?

On June 16, 2026, the Centers for Medicare & Medicaid Services (CMS) published a 60-day notice in the Federal Register under the Paperwork Reduction Act, inviting the public to comment on the proposed new rules around the Medicare Drug Price Negotiation Program, which was created under the Inflation Reduction Act.

This proposed rule (CMS-4215-P) sets the permanent framework and covers the 2029 negotiation cycle, the program’s fourth round, when 20 more Part B and Part D drugs will be selected. Alongside routine updates, CMS proposed several policies with real consequences for mental health innovation and access. Several stand out.

You do not have to be a policy expert to weigh in. CMS weighs both the volume and the specificity of public comments. A short, focused submission from someone who understands mental health research adds something a policy analyst cannot.

Key Issues That Matter for Mental Health and Why Your Voice Matters

Issue	What the proposed rule says	Why your voice matters
Fixed-Combination Drugs and New Routes of Administration (§ 429.125(b)(4)(i))	If a drug is reformulated by adding an ingredient that creates a new formulation and enables a new route of administration, CMS would treat the original and the reformulated version as the same drug for negotiation timing. The reformulation would earn no fresh negotiation clock.	CMS wants to stop reformulations done only to reset the clock, and that goal is reasonable. But in mental health, how a medicine is delivered can matter almost as much as the medicine itself. Long-acting and better-delivered formulations are among the few things that meaningfully improve adherence in serious mental illness. Comments can ask CMS to tell the difference between a delivery change with real clinical benefit and one that is simply gaming the timeline.
Off-Label Uses and Renegotiation (§§ 429.605 and 429.610)	A drug’s total sales, including off-label use, count when CMS decides whether to include it on the list of drugs selected for pricing. But that same off-label use is not necessarily weighed in the actual price negotiation. CMS would consider off-label use only if the manufacturer voluntarily submits it, and only when the use already appears in evidence-based clinical guidelines, which can leave out common psychiatric practice.	Psychiatric drugs are prescribed off-label more than almost any others. If off-label use stays invisible, the negotiated price will not reflect how these medicines are actually used to help people. There is also an odd asymmetry: off-label volume can still pull a drug into selection through total spending. Comments can urge CMS to find a neutral, real-world way to reflect how drugs are truly used in mental health care.
How CMS Defines a Drug’s “Value” (§ 429.510 and the negotiation factors)	When CMS sets a price, it weighs factors like a drug’s “outcomes,” whether it is a “therapeutic advance,” and how it compares to its “therapeutic alternatives.” CMS proposes to define outcomes broadly, reaching functioning, symptoms, and quality of life. Patients, caregivers, and advocacy groups may submit evidence about a drug and its alternatives.	This is where a drug’s value gets decided. CMS’s broad “outcomes” definition is good for mental health, where real progress often looks like staying employed, keeping housing, and staying out of the hospital. But treating drugs within a class as interchangeable “alternatives” ignores a basic clinical fact: antipsychotics are not interchangeable, and switching can carry real risk. Comments can urge CMS to weigh real mental health outcomes and to respect that patients respond differently to different medicines.
Temporary Floor for Small Biotech Drugs (§ 429.440)	Sets a temporary price floor so a negotiated price cannot fall below 66% of a drug’s 2021 benchmark, for the 2029 and 2030 cycles. It applies only to drugs that already qualified for the small biotech exemption in the earlier cycles. The company must apply, and the protection generally falls away if the small biotech is acquired by a larger manufacturer.	Most mental health innovation starts with small companies, and many are acquired well before a drug is approved. A protection that disappears on acquisition, and cannot transfer with the drug, does little for the developers taking the earliest risks. It can even lower an asset’s value to a buyer. Comments can urge CMS to let the protection follow the drug and the science, not just the company.
Deadline: August 17, 2026	Submit comments electronically at regulations.gov. Reference file code CMS-4215-P in the search field and follow the instructions for submitting a comment. A full comment letter can be attached as a PDF.	CMS weighs both the number and the specificity of comments. Even a brief, focused submission from your organization adds to the record and helps put the mental health perspective on paper.

Advocates, patients, caregivers, sites, and community organizations all have standing to comment. The rule also gives interested parties a formal way to submit evidence into the negotiation itself, so your voice and your experience can help shape how CMS values mental health treatment. Real-world perspectives on how these rules affect access and the pipeline of new therapies are exactly what CMS needs to hear.

——————————————-

Once you click on the SUBMIT COMMENT button, you will see a confirmation box pop up.

Why This Matters for Mental Health Research

Mental health drug development is already slow, expensive, and underfunded relative to the need. Three things make this field different from most others: (1) Much of the innovation comes from small companies. (2) Delivery and adherence are central to whether treatment actually works. And (3) off-label use is the norm, not the exception.

Each provision in this rule, taken on its own, is a reasonable step. Taken together, they lean against the very features that define how mental health treatments get discovered and delivered. Affordable access and a healthy pipeline are not opposing goals. A rule that protects affordability today should not quietly weaken the treatments patients will depend on tomorrow. Public comment is how the mental health community helps CMS strike that balance.

Comments are due August 17, 2026.

How to Comment

Go to Regulations.gov, docket CMS-2026-2080.
Reference file code CMS-4215-P.
Type a short comment, and/or attach a full letter as a PDF or Word file.
When prompted, you can submit as an organization or as an individual.
Submit before 5pm ET on August 17, 2026. Remember that comment text is public.

Feel free to use our comment below as a starting point and adapt it for your own submission (click to open).

This issue is part of STARR’s broader work on access and trust in mental health clinical research. It connects to our advocacy on drug pricing, patient access, and the role of public-private partnership in bringing new treatments to the people who need them.